Conclusion from Article from Renal and Urology News Published July 24, 2017. “In conclusion, real-world data from this analysis have demonstrated that ferric citrate is an effective phosphate binder with 65% of the patients within the target phosphorus range and overall increased iron stores and maintenance of Hgb levels following 6 months of treatment,” Dr Pergola and colleagues concluded in Clinical Nephrology
Q2 numbers with all IMS data
IMS from 4/7/17 - 6/30/17 in date sequence 744, 785, 791, 851, 862, 921, 880, 903, 780, 869, 1004, 996, 999 IMS total for Q2 = 11385 Estimate of total scripts with 55% IMS + 45% DVA/FMC = 20700 Revenue factor from Q1 ( 10,5 m$ /15800 scripts * 1000) = 0,6646
Estimate net sales revenue Auryxia in the US = 13,76 m$ Estimate royalties from Japan (Q1 value) = 1,3 m$ Total revenue Auryxia = 15,06 m$
Outstanding 55 million US dollar for milestone payments for Riona
Analyst Ratings For Keryx Biopharmaceuticals (NASDAQ:KERX) Today, Cowen and Company reiterated its Market Perform rating on Keryx Biopharmaceuticals (NASDAQ:KERX). There are 5 hold ratings, 4 buy ratings on the stock. The current consensus rating on Keryx Biopharmaceuticals (NASDAQ:KERX) is Hold (Score: 2.44) with a consensus target price of $8.60 per share, a potential 17.97% upside
I guess everyone is waiting for the 2nd quarter conference call tomorrow. We should see better growth and increased growth there after.
KERYX Upgrade ---- Zacks Investment Research, Inc. upgrades KERYX from HOLD to a BUY on 07/26/2017.
Definitely nobody betting on positive news ah I am hoping for good news for everyone.
Will close around 7.50 and 8.50 by end of this week!
Columbine Capital Services, Inc. upgrades KERX from Neutral to Favorable on 07/22/2017.
I don't know if this has been discussed before. But what is the effect of Auryxia on phosphate levels if those are normal? I can imagine that lots of the CKD-patients with anemia have normal phosphate levels. Could the FDA have a problem with that?
Even Morgan Staley raises PT to 7$
Morgan Stanley Keeps a “Equal-Weight” Rating on Keryx Biopharmaceuticals (KERX) and $7 Target, Wafra Investment Advisory Group Upped Devon Energy Corp. (DVN) Holding By $9.23 Million July 25, 2017 - By Marguerite Chambers
Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals has $18 highest and $1.80 lowest target. $8.79’s average target is 18.94% above currents $7.39 stock price. Keryx Biopharmaceuticals had 32 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group on Thursday, July 20 with “Buy”. JMP Securities maintained it with “Market Outperform” rating and $16 target in Wednesday, March 9 report. FBR Capital downgraded the shares of KERX in report on Tuesday, August 2 to “Market Perform” rating. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) has “Sell” rating given on Thursday, August 6 by BTIG Research. The stock has “Buy” rating by Ladenburg Thalmann on Tuesday, August 2. Maxim Group upgraded it to “Buy” rating and $7 target in Wednesday, November 9 report. The firm has “Hold” rating given on Tuesday, August 2 by Brean Capital. The firm has “Hold” rating given on Tuesday, August 2 by Stifel Nicolaus. The company was initiated on Thursday, September 3 by Citigroup. On Thursday, August 6 the stock rating was maintained by Maxim Group with “Buy”.
After the options expiary i would thing this should have been green and not red. It looks like the earnings report will tell us all.
KERX Upgrade ----- Thomson Reuters/Verus upgrades KEYX BIOPHARMACEUTICALS INC from Hold to BUY on 07/24/2017. Now is the time to be buying or adding! KERX at $15 to $18 next summer.
IMS was 994 from StockTwits
2Q17 earning announcement is 10 days earlier than the usual of last few quarters. I think it should be good news by KERX.
Hold firm - will go back over $8 just takes time. We should be in the teens.
GREAT NEWS! INSTITUTIONS ADD 1.8M SHARES FOR THE Q SEE FOR YOURSELF:
Keryx Biopharmaceuticals Inc, Inst Holders, 2Q 2017 (KERX) BY Dow Jones & Company, Inc. — 3:53 AM ET 07/21/2017
The following table shows the largest shareholders in KERYX BIOPHARMACEUTICALS INC COM (KERX) for the quarter ended June 30, 2017, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 06/30/2017
Institution Shares Shares % Last Held Changed Held Report
The Baupost Group LLC 25,791,678 0 23.778 03/31 The Vanguard Group Inc. 6,848,748 302,986 6.314 03/31 Abrams Capital Management LP 5,719,176 0 5.273 03/31 BlackRock Fund Advisors 5,012,677 20,205 4.621 03/31 SSgA Funds Management Inc. 3,479,370 582,624 3.208 03/31 Fidelity Management & Research 2,314,664 (155,500) 2.134 03/31 Columbia Management Investment 1,593,401 (182,110) 1.469 03/31 Rice Hall James & Associates 1,340,649 39,656 1.236 03/31 ClearBridge LLC 1,302,640 1,302,640 1.201 03/31 Millennium Management LLC 1,274,420 417,186 1.175 03/31 Northern Trust Investments In 1,019,440 62,298 0.940 03/31 Old West Investment Management 828,914 619,285 0.764 03/31 Geode Capital Management LLC 808,787 58,270 0.746 03/31 Goldman Sachs & Co. LLC (Priva 664,141 18,247 0.612 03/31 The Bank of New York Mellon Co 533,979 (459,388) 0.492 03/31 Charles Schwab Investment Mana 436,718 25,842 0.403 03/31 Rhenman & Partners Asset Manag 425,111 0 0.392 06/30 Boston Partners Global Investo 409,051 0 0.377 03/31 Morgan Stanley & Co. LLC 328,929 (27,927) 0.303 03/31 BlackRock Investment Managemen 292,015 (2,383) 0.269 03/31 Iridian Asset Management LLC 265,110 36,540 0.244 03/31 UBS Financial Services Inc. 262,261 26,089 0.242 03/31 Royce & Associates LP 256,725 0 0.237 03/31 The Dreyfus Corp. 249,825 2,392 0.230 03/31 TIAA-CREF Investment Managemen 212,760 (14,526) 0.196 03/31 Knoll Capital Management LP 200,000 0 0.184 03/31 The California Public Employee 196,600 (8,500) 0.181 03/31 Parametric Portfolio Associate 192,982 72,436 0.178 03/31 Virtus ETF Advisers LLC 183,907 17,684 0.170 03/31 Credit Suisse Securities (USA) 166,497 88,411 0.154 03/31 Group One Trading LP 160,132 (108,595) 0.148 03/31 California State Teachers' Ret 155,458 (7,300) 0.143 03/31 Citadel Advisors LLC 148,166 100,857 0.137 03/31 A.R.T. Advisors LLC 147,400 147,400 0.136 03/31 Mellon Capital Management Corp 145,888 1,663 0.134 03/31 Endurant Capital Management LP 142,100 142,100 0.131 03/31 New York State Common Retireme 140,578 1 0.130 03/31 Teachers Advisors LLC 138,874 0 0.128 03/31 AllianceBernstein LP 137,640 (11,700) 0.127 03/31 Schweizerische Nationalbank (I 130,500 0 0.120 03/31 D. E. Shaw & Co. LP 126,568 (53,703) 0.117 03/31 Clough Capital Partners LP 106,700 28,100 0.098 03/31 Morgan Stanley Smith Barney LL 102,252 2,008 0.094 03/31 Point72 Asset Management LP 100,000 100,000 0.092 03/31 Prospect Capital Advisors LLC 100,000 100,000 0.092 03/31 RhumbLine Advisers Ltd. Partne 99,376 6,750 0.092 03/31 First Trust Advisors LP 83,220 (80,961) 0.077 03/31 Shufro Rose & Co. LLC 73,200 500 0.067 03/31 Frontier Wealth Management LLC 71,110 (800) 0.066 03/31 CTC myCFO LLC 70,467 0 0.065 06/30
13F data provided by: Factset Research Systems Inc.; Please send questions to email@example.com. Copyright, Factset Research Systems, 2017. All Rights Reserved.
(END) Dow Jones Newswires 07-21-17 0353ET
More KERX News
Keryx put volume heavy and directionally bearish (TheFlyOnTheWall) TheFlyOnTheWall - 2:35 PM ET 07/19/2017 Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2017 Financial Results on Thursday, July 27, 2017 GlobeNewswire - 8:31 AM ET 07/19/2017 Zacks Investment Research, Inc. downgrades KERYX BIOPHARMACEUTICALS INC from BUY to HOLD. Investars Analyst Actions - private - 7:34 PM ET 07/15/2017
Good news bad news on generic Renvela. The bad: (Leaving aside Impax imbroglio from long ago), not many expected Aurobindo to get approval this quickly for the tablets. It remains to be seen how many others such as Mylan & Impax gain approval. The good: It is not an easy drug to make and may remain cost prohibitive if others do not enter the market. Ferric citrate remains an worthy alternative. Either way the real value in Keryx is the newly applied for indication
Script trends point to a 2%+ weekly growth trend which puts KERX on track for Aurxyia PRODUCT revenue of $62M+ for the year. Expect PRODUCT revenue guidance to be raised from $56-60M to $60-64M on the upcoming conference call. This should send the stock back above $8..
EARNINGS COULD SEND THIS BIOTECH STOCK SOARING by Josh Selway | KERX
We've been watching small-cap stocks closely in recent weeks, since this group doesn't appear to be as overbought as their large-cap peers. With this in mind, there are a number of low-priced biotech stocks that could be worth monitoring, including Keryx Biopharmaceuticals (NASDAQ:KERX). With earnings due tomorrow before the open, KERX stock could have upside potential, from a contrarian perspective.
But taking a quick step back, it's worth noting that data from Schaeffer's Senior Quantitative Analyst Rocky White suggests analysts have failed to appropriately adjust their positions on biotechs in general, despite their strong performance on the charts. Specifically, the percentage of "buy" ratings from analysts have edged down to 64% compared to 66% a year ago, even though the average year-to-date return of the stocks under our "Biomedics Genetics" umbrella is 44.1%.
Likewise, Keryx shares are up 27% year-to-date to trade at $7.46, touching a two-year high of $8.38 two weeks ago. Now, the shares appear to be bouncing from their most recent low near the 30-day moving average -- a trendline that served as support from March through early June.
But analysts are mostly skeptical, with more than half handing out tepid "hold" ratings. Plus, the average 12-month price target stands at $8.14 -- a slim 9.3% from current trading levels. A big post-earnings move to the upside may encourage analysts to upgrade the stock and/or raise their price targets, which could result in additional tailwinds.
A short-squeeze situation could also boost KERX stock. Roughly one-quarter of the stock's float is sold short, which equates to almost 13 days' worth of buying power, based on average daily volumes. A mass exodus of these bears would also fuel more upside.
For what it's worth, Keryx Biopharmaceuticals shares have a solid post-earnings history, including a 6.6% jump in the session after the drugmaker's last earnings report. This time around, the options market is pricing in a 7.8% swing, in either direction, and open interest levels might be pointing toward enthusiasm from these traders. Specifically, calls account for the top seven open interest positions on KERX, with the September 9 strike at the top of the list.